Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia
Learn more

Improving Oxygen Availability

Novel Mechanism of Action

Lead drug candidate Trans sodium crocetinate (TSC) enhances the oxygen diffusion process, supporting normal, physiologic levels of oxygen diffusion at uptake and delivery.

Selective for Hypoxic Tissue

In animal models, TSC’s mechanism of action enhanced oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Demonstrated Safety Profile

TSC has been safe and well tolerated in over 200 subjects dosed in prior preclinical and clinical studies.

OUR TECHNOLOGY

Lead drug
candidate, Trans sodium
crocetinate (TSC)

We are developing our lead product, TSC, to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.

Learn more

News

Latest press releases, announcements, and more.

Diffusion Pharmaceuticals Issues Letter to Shareholders

 Diffusion Pharmaceuticals Issues Letter to Shareholders 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

 Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

 Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

 Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum

 Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 21, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting

 Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 18, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients

 Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study

 Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Participants in TCOM Study

 Diffusion Pharmaceuticals Doses First Participants in TCOM Study 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 18, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

News Releases

Podcasts

Fueling Life, a podcast from Diffusion Pharmaceuticals.

Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption
 Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption 150 150 Diffusion Pharmaceuticals Inc.

Chief Medical Officer Dr. Chris Galloway previews Diffusion’s Altitude Trial, the second in a trio of Oxygenation Trials that will collectively inform late phase programs and the clinical development plan for lead drug candidate TSC.

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen
 Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen 150 150 Diffusion Pharmaceuticals Inc.

Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.

Episode 1: The Science of Solving for Hypoxia
 Episode 1: The Science of Solving for Hypoxia 150 150 Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals CEO Robert Cobuzzi, Jr., PhD discusses cellular oxygen deficiency, the TSC development plan, and potential future applications for this small molecule therapeutic with a novel MOA.

Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals
 Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals 150 150 Diffusion Pharmaceuticals Inc.

This podcast will discuss hypoxia, a potentially fatal shortage of oxygen in a body tissue, and cover the development plan for lead product candidate TSC, which enhances oxygen diffusion to hypoxic tissue.

Listen on Spotify

Back to top